Advertisement
DMAC vs EDIT
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DMAC is a StrongBuy and EDIT is a Hold.
DMAC's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for DMAC turned positive on October 22, 2026. Looking at past instances where DMAC's MACD turned positive, the stock continued to rise in 49 of 50 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on DMAC as a result. In 84 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 89%.
The 50-day moving average for DMAC moved above the 200-day moving average on October 13, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +6.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where DMAC advanced for three days, in 218 of 258 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Aroon Indicator entered an Uptrend today. In 131 of 159 cases where DMAC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.
Bearish Trend Analysis
The 10-day RSI Indicator for DMAC moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 24 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 77%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 47 of 58 cases where DMAC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DMAC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
DMAC broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 32 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. DMAC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.166) is normal, around the industry mean (3.498). P/E Ratio (-13.000) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 82 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
EDIT sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for EDIT moved below the 200-day moving average on November 09, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 42 of 48 cases where EDIT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
EDIT broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for EDIT entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on EDIT as a result. In 67 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for EDIT just turned positive on October 27, 2026. Looking at past instances where EDIT's MACD turned positive, the stock continued to rise in 38 of 48 cases over the following month. The odds of a continued upward trend are 79%.
EDIT moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +7.84% 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in 182 of 227 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 31 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.749) is normal, around the industry mean (3.498). P/E Ratio (-3.894) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (5.855) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 70 (best 1 - 100 worst), indicating slightly worse than average price growth. EDIT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
DMAC | EDIT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 38 | 81 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 69 Overvalued | 53 Fair valued | |
PROFIT vs RISK RATING 1..100 | 32 | 100 | |
SMR RATING 1..100 | 99 | 99 | |
PRICE GROWTH RATING 1..100 | 35 | 70 | |
P/E GROWTH RATING 1..100 | 82 | 31 | |
SEASONALITY SCORE 1..100 | 85 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
EDIT's Valuation (53) in the Biotechnology industry is in the same range as DMAC (69). This means that EDIT’s stock grew similarly to DMAC’s over the last 12 months.
DMAC's Profit vs Risk Rating (32) in the Biotechnology industry is significantly better than the same rating for EDIT (100). This means that DMAC’s stock grew significantly faster than EDIT’s over the last 12 months.
DMAC's SMR Rating (99) in the Biotechnology industry is in the same range as EDIT (99). This means that DMAC’s stock grew similarly to EDIT’s over the last 12 months.
DMAC's Price Growth Rating (35) in the Biotechnology industry is somewhat better than the same rating for EDIT (70). This means that DMAC’s stock grew somewhat faster than EDIT’s over the last 12 months.
EDIT's P/E Growth Rating (31) in the Biotechnology industry is somewhat better than the same rating for DMAC (82). This means that EDIT’s stock grew somewhat faster than DMAC’s over the last 12 months.
| DMAC | EDIT | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 77% | N/A |
| Stochastic ODDS (%) | 1 day ago 81% | 1 day ago 88% |
| Momentum ODDS (%) | 1 day ago 89% | 1 day ago 80% |
| MACD ODDS (%) | 1 day ago 90% | 1 day ago 79% |
| TrendWeek ODDS (%) | 1 day ago 83% | 1 day ago 82% |
| TrendMonth ODDS (%) | 1 day ago 82% | 1 day ago 89% |
| Advances ODDS (%) | 1 day ago 84% | 1 day ago 80% |
| Declines ODDS (%) | 11 days ago 81% | 8 days ago 90% |
| BollingerBands ODDS (%) | 1 day ago 89% | 1 day ago 86% |
| Aroon ODDS (%) | 1 day ago 82% | 1 day ago 88% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DMAC’s FA Score shows that 1 FA rating(s) are green while EDIT’s FA Score has 1 green FA rating(s).
- DMAC’s FA Score: 1 green, 4 red.
- EDIT’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DMAC’s TA Score shows that 5 TA indicator(s) are bullish while EDIT’s TA Score has 4 bullish TA indicator(s).
- DMAC’s TA Score: 5 bullish, 4 bearish.
- EDIT’s TA Score: 4 bullish, 5 bearish.
Price Growth
DMAC (@Biotechnology) experienced а +1.19% price change this week, while EDIT (@Biotechnology) price change was +7.00% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.97%. For the same industry, the average monthly price growth was -8.33%, and the average quarterly price growth was +85.08%.
Reported Earning Dates
DMAC is expected to report earnings on Nov 12, 2026.
EDIT is expected to report earnings on Feb 25, 2027.
Industries' Descriptions
@Biotechnology (+2.97% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
DMAC and
Correlation & Price change
A.I.dvisor indicates that over the last year, DMAC has been loosely correlated with ANNX. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if DMAC jumps, then ANNX could also see price increases.
| Ticker / NAME | Correlation To DMAC | 1D Price Change % | ||
|---|---|---|---|---|
| DMAC | 100% | +3.10% | ||
| ANNX - DMAC | 47% Loosely correlated | +0.71% | ||
| EDIT - DMAC | 47% Loosely correlated | +7.00% | ||
| TSHA - DMAC | 45% Loosely correlated | +0.92% | ||
| VIR - DMAC | 44% Loosely correlated | +11.75% | ||
| SLDB - DMAC | 44% Loosely correlated | +6.53% | ||
More | ||||